Senti Biosciences, Inc. (NASDAQ:SNTI) Sees Large Decline in Short Interest

Senti Biosciences, Inc. (NASDAQ:SNTI) was the target of a significant decline in short interest during the month of April. As of April 15th, there was short interest totalling 165,200 shares, a decline of 22.7% from the March 31st total of 213,800 shares. Approximately 0.6% of the company’s stock are short sold. Based on an average daily volume of 81,400 shares, the days-to-cover ratio is currently 2.0 days.

Senti Biosciences Trading Up 6.8 %

Shares of SNTI stock traded up $0.02 during trading hours on Monday, reaching $0.31. 43,472 shares of the company’s stock were exchanged, compared to its average volume of 104,664. The stock’s 50 day moving average is $0.37 and its 200-day moving average is $0.41. Senti Biosciences has a fifty-two week low of $0.27 and a fifty-two week high of $1.10. The company has a market cap of $14.17 million, a price-to-earnings ratio of -0.19 and a beta of 2.96.

Senti Biosciences (NASDAQ:SNTI) last posted its quarterly earnings data on Thursday, March 21st. The company reported ($0.42) earnings per share (EPS) for the quarter. Senti Biosciences had a negative net margin of 2,692.82% and a negative return on equity of 74.59%. Equities analysts anticipate that Senti Biosciences will post -1 EPS for the current year.

Hedge Funds Weigh In On Senti Biosciences

Several hedge funds have recently made changes to their positions in SNTI. TD Asset Management Inc grew its stake in Senti Biosciences by 88.4% during the 3rd quarter. TD Asset Management Inc now owns 241,208 shares of the company’s stock valued at $102,000 after purchasing an additional 113,172 shares during the last quarter. ARK Investment Management LLC lifted its holdings in shares of Senti Biosciences by 7.9% during the fourth quarter. ARK Investment Management LLC now owns 1,969,860 shares of the company’s stock worth $1,300,000 after purchasing an additional 143,785 shares during the period. Finally, 8VC GP I LLC purchased a new stake in Senti Biosciences in the fourth quarter valued at approximately $1,675,000. 25.73% of the stock is owned by institutional investors and hedge funds.

Senti Biosciences Company Profile

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.